PIRS News and Press, Pieris Pharmaceuticals Inc. From 03/25/21

Pieris Pharmaceuticals (PIRS) soars 15% premarket after Seagen (SGEN) makes a strategic equity investment in the company as part of an ongoing collaboration between them.The companies have amended their existing immuno-oncology agreement around joint development and commercial right...

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercis...

BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced ...

BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today anno...

The FDA has lifted partial clinical hold on Phase 1 studies evaluating Pieris Pharmaceuticals' ([[PIRS]] +3.4%) lead candidate, PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.The FDA instituted a partial...

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...

Ocugen (OCGN) +127%.The9 Limited (NCTY +62% after signing a legally binding cooperation and investment term sheet.Bionano Genomics (BNGO +44% on publishing study on Autism Risk Genes.ViewRay (VRAY +23% on preliminary Q4 results.AirNet Technology (ANTE +28%&#...

Pieris Pharmaceuticals, Inc. (PIRS) Q3 2020 Results Conference Call November 04, 2020 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participa...

Pieris Pharmaceuticals (PIRS) Q3 net loss was $14.3M or EPS of$0.26, misses consensus by $0.13. This compares to a net loss of $2.6M or EPS loss of $0.05.G&A expense were $4.1M, compared to $4.8M.R&D expenses were $11.8M, compared to $13.2M.Cash, cash equivalents, and investments...

Pieris Pharmaceuticals (PIRS): Q3 GAAP EPS of -$0.26 misses by $0.13.Revenue of $2.94M (-80.6% Y/Y) misses by $8.78M.Press Release For further details see: Pieris Pharmaceuticals EPS misses by $0.13, misses on revenue